同行评审出版物

投资者信息中心

公告与通函

投资者演示文稿

ag8亚游联系方式

ag8亚游日历

发布公司通讯

关于ag亚游官网

战略顾问委员会

高级科学顾问委员会

科学研发

同行评审出版物

科研壁报

2022 ADA Poster

Dorzagliatin, a dual-acting glucokinase activator, improves insulin secretion and glucose sensitivity in glucokinase-maturity-onset diabetes of the young (GK-MODY) and recent-onset type 2 diabetes.

2022 ADA Poster

Glucokinase Activator Restore Glucose Sensitivity and Early Phase Insulin Secretion in T2DM Patients: A Post-hoc Analysis of the Phase III Trials of Dorzagliatin.

2022 ADA Poster

Dorzagliatin Effect in Diabetes Remission (DREAM Study)

2021 ADA Poster

Glucokinase Activator Dorzagliatin (HMS5552) Regulates GLP1 Release in T2D Patients and is Synergistic with Sitagliptin and Empagliflozin in Optimizing Beta Cell Function.

2021 ADA Poster

Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control in Combination with Metformin in Chinese T2DM Patients in a 52-Week Phase 3 Clinical Trial (DAWN Study)

2020 ADA Poster

Dorzagliatin as a Glucose Sensitizer Achieved Sustained Glycemic Control in Drug-Naïve T2D Patients in a 52-Week Phase 3 Monotherapy Trial (SEED Study)

2

关注我们

Copyright © 2024 ag亚游官网互联网药品信息服务资格证书编号: （沪）-非经营-2022-0079
沪ICP备14036654号-1

沪公网安备 31011502013809号隐私声明使用条款

搜索

我们如何使用Cookies

ag8亚游使用 Cookie 来改进网站的使用。继续使用本网站即表示您同意使用这些 Cookie。如需了解更多关于 Cookie 的信息，请阅读我们的隐私声明。

全部接受

x